Search
Now showing items 11-13 of 13
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.
(2017-05-15)
The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very effective, a major clinical limitation ...
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.
(BMJ PUBLISHING GROUP, 2018-01-01)
OBJECTIVE: Colorectal cancer (CRC) leads to significant morbidity/mortality worldwide. Defining critical research gaps (RG), their prioritisation and resolution, could improve patient outcomes. DESIGN: RG analysis was ...
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
(MASSACHUSETTS MEDICAL SOC, 2017-11-09)
BACKGROUND: The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such ...